Your browser is no longer supported. Please, upgrade your browser.
KURA Kura Oncology, Inc. daily Stock Chart
KURA [NASD]
Kura Oncology, Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own0.10% Shs Outstand51.63M Perf Week-12.28%
Market Cap1.63B Forward P/E- EPS next Y-1.91 Insider Trans-91.96% Shs Float49.48M Perf Month3.89%
Income-74.00M PEG- EPS next Q-0.40 Inst Own95.30% Short Float6.05% Perf Quarter67.43%
Sales- P/S- EPS this Y12.40% Inst Trans1.13% Short Ratio4.61 Perf Half Y187.14%
Book/sh6.24 P/B4.79 EPS next Y-15.80% ROA-27.50% Target Price30.50 Perf Year103.12%
Cash/sh6.21 P/C4.82 EPS next 5Y19.93% ROE-30.20% 52W Range6.35 - 35.25 Perf YTD117.60%
Dividend- P/FCF- EPS past 5Y-42.90% ROI- 52W High-15.12% Beta2.31
Dividend %- Quick Ratio18.40 Sales past 5Y- Gross Margin- 52W Low371.18% ATR1.67
Employees71 Current Ratio18.40 Sales Q/Q- Oper. Margin- RSI (14)46.81 Volatility6.50% 5.19%
OptionableYes Debt/Eq0.02 EPS Q/Q-3.40% Profit Margin- Rel Volume0.91 Prev Close29.00
ShortableYes LT Debt/Eq0.02 EarningsAug 06 AMC Payout- Avg Volume650.45K Price29.92
Recom1.80 SMA20-6.11% SMA507.27% SMA20072.02% Volume593,607 Change3.17%
Jul-07-20Initiated Credit Suisse Outperform $27
May-05-20Initiated Barclays Overweight $24
Jul-18-19Initiated Deutsche Bank Buy $28
Nov-09-18Initiated Piper Jaffray Overweight
Aug-01-18Initiated H.C. Wainwright Buy $31
Oct-13-16Resumed Leerink Partners Outperform $15
Jan-22-16Initiated JMP Securities Mkt Outperform
Dec-30-15Initiated Oppenheimer Outperform $16
Dec-16-15Initiated Citigroup Buy
Oct-07-20 07:30AM  
Sep-15-20 12:21AM  
Sep-08-20 07:30AM  
Aug-26-20 01:33PM  
08:31AM  
Aug-25-20 07:30AM  
Aug-06-20 04:05PM  
Aug-04-20 07:30AM  
Jul-30-20 07:30AM  
Jul-29-20 10:23AM  
Jul-17-20 10:37AM  
Jun-16-20 10:46AM  
Jun-11-20 07:30AM  
May-29-20 08:00AM  
May-13-20 05:00PM  
03:18AM  
May-08-20 04:03PM  
May-07-20 07:30AM  
May-06-20 09:00AM  
May-05-20 04:01PM  
11:30AM  
May-04-20 04:05PM  
Apr-29-20 07:30AM  
Apr-28-20 03:09PM  
Mar-10-20 03:18AM  
Mar-03-20 07:30AM  
Feb-25-20 04:03PM  
Feb-19-20 04:05PM  
Feb-18-20 04:05PM  
Jan-24-20 10:44AM  
Jan-23-20 04:05PM  
Jan-21-20 04:09AM  
Jan-09-20 07:30AM  
Jan-06-20 07:30AM  
Dec-16-19 07:30AM  
Dec-10-19 02:21PM  
Dec-08-19 12:00PM  
Nov-26-19 07:30AM  
Nov-25-19 05:51AM  
Nov-15-19 04:29PM  
Nov-12-19 07:30AM  
Nov-09-19 02:26PM  
Nov-06-19 09:06AM  
Nov-05-19 04:05PM  
Nov-04-19 07:30AM  
Oct-30-19 07:30AM  
Oct-29-19 11:50AM  
Oct-23-19 04:05PM  
Oct-16-19 04:30PM  
Oct-15-19 07:30AM  
Oct-01-19 01:05AM  
Sep-16-19 07:30AM  
Sep-03-19 07:30AM  
Aug-29-19 07:30AM  
Aug-12-19 04:05PM  
Aug-07-19 07:30AM  
Aug-03-19 12:08AM  
Jul-25-19 07:30AM  
Jul-24-19 07:30AM  
Jul-11-19 07:30AM  
Jul-02-19 09:15AM  
Jun-23-19 08:50AM  
08:48AM  
Jun-21-19 04:30PM  
Jun-18-19 11:31PM  
04:01PM  
10:46AM  
Jun-17-19 09:31AM  
Jun-14-19 10:03AM  
07:48AM  
07:00AM  
May-15-19 12:14PM  
May-09-19 01:15PM  
May-07-19 08:49PM  
05:54PM  
04:05PM  
Apr-30-19 07:30AM  
Apr-25-19 12:36PM  
Apr-02-19 04:04PM  
Mar-29-19 07:10AM  
Mar-27-19 07:16AM  
Mar-06-19 07:30AM  
Mar-05-19 07:13PM  
04:03PM  
07:30AM  
Feb-26-19 07:30AM  
Feb-20-19 07:30AM  
Feb-19-19 07:40AM  
Jan-18-19 10:00AM  
Jan-03-19 07:30AM  
Dec-15-18 11:21PM  
Dec-03-18 09:19AM  
Dec-02-18 12:00PM  
Nov-30-18 07:50AM  
Nov-28-18 07:30AM  
Nov-08-18 07:30AM  
Nov-06-18 07:30AM  
Nov-05-18 06:14PM  
04:05PM  
07:30AM  
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILSON TROY EDWARDPresident and CEOOct 08Option Exercise6.1550,370309,77678,466Oct 08 06:55 PM
WILSON TROY EDWARDPresident and CEOOct 08Sale34.00106,7363,629,0240Oct 08 06:55 PM
WILSON TROY EDWARDPresident and CEOOct 08Sale34.0050,3701,712,58028,096Oct 08 06:55 PM
WILSON TROY EDWARDPresident and CEOOct 07Option Exercise6.154,58628,20432,682Oct 08 06:55 PM
WILSON TROY EDWARDPresident and CEOOct 07Sale32.0099,9003,196,800106,736Oct 08 06:55 PM
WILSON TROY EDWARDPresident and CEOOct 07Sale34.004,586155,92428,096Oct 08 06:55 PM
WILSON TROY EDWARDPresident and CEOOct 06Sale32.001003,200206,636Oct 08 06:55 PM
FORD KATHLEENChief Operating OfficerSep 15Option Exercise19.436,250121,4386,250Sep 15 07:25 PM
FORD KATHLEENChief Operating OfficerSep 15Sale29.436,250183,9380Sep 15 07:25 PM
GRASSO MARCCFO, CBOSep 14Option Exercise29.0010,000290,00010,000Sep 15 07:23 PM
FORD KATHLEENChief Operating OfficerSep 14Option Exercise19.436,250121,4386,250Sep 15 07:25 PM
FORD KATHLEENChief Operating OfficerSep 14Sale29.436,250183,9380Sep 15 07:25 PM
GRASSO MARCCFO, CBOSep 14Sale29.0010,000290,0000Sep 15 07:23 PM
WILSON TROY EDWARDPresident and CEOSep 14Sale28.8298,4902,838,876206,736Sep 15 07:22 PM
WILSON TROY EDWARDPresident and CEOSep 11Option Exercise6.1517,926110,24546,022Sep 15 07:22 PM
WILSON TROY EDWARDPresident and CEOSep 11Sale28.0048513,580305,226Sep 15 07:22 PM
WILSON TROY EDWARDPresident and CEOSep 11Sale28.0017,926501,92828,096Sep 15 07:22 PM
WILSON TROY EDWARDPresident and CEOSep 10Option Exercise6.1537,030227,73565,126Sep 10 06:05 PM
WILSON TROY EDWARDPresident and CEOSep 10Sale28.001,02528,700305,711Sep 10 06:05 PM
WILSON TROY EDWARDPresident and CEOSep 10Sale28.0037,0301,036,84028,096Sep 10 06:05 PM
GRASSO MARCCFO, CBOSep 08Option Exercise15.4710,000154,70010,000Sep 10 06:04 PM
WILSON TROY EDWARDPresident and CEOSep 08Sale26.0050,0001,300,000306,736Sep 10 06:05 PM
GRASSO MARCCFO, CBOSep 08Sale26.0010,000260,0000Sep 10 06:04 PM
GRASSO MARCCFO, CBOAug 25Option Exercise15.4710,000154,70010,000Aug 26 06:22 PM
WILSON TROY EDWARDPresident and CEOAug 25Option Exercise6.1423,053141,48651,149Aug 26 06:24 PM
WILSON TROY EDWARDPresident and CEOAug 25Sale22.3723,053515,78828,096Aug 26 06:24 PM
GRASSO MARCCFO, CBOAug 25Sale23.0010,000230,0000Aug 26 06:22 PM
WILSON TROY EDWARDPresident and CEOAug 24Option Exercise4.806,56831,52634,664Aug 26 06:24 PM
WILSON TROY EDWARDPresident and CEOAug 24Sale22.046,568144,77028,096Aug 26 06:24 PM
WILSON TROY EDWARDPresident and CEOAug 19Option Exercise4.8011,91357,18240,009Aug 19 06:38 PM
WILSON TROY EDWARDPresident and CEOAug 19Sale22.0911,913263,19628,096Aug 19 06:38 PM
WILSON TROY EDWARDPresident and CEOAug 18Option Exercise4.805212,50128,617Aug 19 06:38 PM
WILSON TROY EDWARDPresident and CEOAug 18Sale22.0052111,46228,096Aug 19 06:38 PM
WILSON TROY EDWARDPresident and CEOAug 17Option Exercise4.8012,90161,92540,997Aug 19 06:38 PM
WILSON TROY EDWARDPresident and CEOAug 17Sale22.0050,0001,100,000356,736Aug 19 06:38 PM
WILSON TROY EDWARDPresident and CEOAug 17Sale22.0012,901283,86828,096Aug 19 06:38 PM
GRASSO MARCCFO, CBOAug 07Option Exercise15.477,102109,86810,000Aug 11 05:02 PM
GRASSO MARCCFO, CBOAug 07Sale20.0010,000200,0000Aug 11 05:02 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.